ASCO 2019: Final Results of KRISTINE Trial of Neoadjuvant Regimens in HER2-Positive Breast Cancer
New Trastuzumab Biosimilar Approved by the FDA
ASCO 2019: Can Clinical Risk Stratification Predict Chemotherapy Benefit in Early Breast Cancer?
Targeting Mitochondrial Metabolism in Triple-Negative Breast Cancer
Lifetime Incidence of Brain Metastasis in Elderly Survivors of Breast Cancer
Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer
Eribulin Versus Vinorelbine in Locally Recurrent or Metastatic Breast Cancer
Does Primary Care Appointment Time Affect Breast Cancer Screening Rates?
14th Annual School of Breast Oncology® Online
NCCN Continuing Education in Breast Cancer
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of HER2-Positive Breast Cancer (login required)
Adding Evidence to Front-Line Therapy of Hormone Receptor–Positive Breast Cancer (login required)
Yale Cancer Center/Smilow Cancer Hospital
Memorial Sloan Kettering Cancer Center
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
Talazoparib (Breast Cancer)
After Breast Cancer Diagnosis (ABCD)
Young Survival Coalition
Sisters Network, Inc.